Agoracom: Small Cap Investment - Zenith Epigenetics - Prostate cancer study - combining two existing therapies could extend life by 37%

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

RVX_Anonymous

Rank: Mail Room [?]

Points: 38 [?]

Votes: 4 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Prostate cancer study - combining two existing therapies could extend life by 37%

posted on Jun 03, 2017 09:58AM

https://www.theguardian.com/society/2017/jun/03/prostate-cancer-therapy-study-abiraterone

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply